These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21574175)

  • 1. FAME, a novel conditioning regimen for allogeneic stem cell transplantation for lymphoma, does not earn fame.
    Ashizawa M; Kako S; Wada H; Sakamoto K; Sato M; Terasako K; Kimura S; Kikuchi M; Nakasone H; Okuda S; Yamazaki R; Oshima K; Nishida J; Kanda Y
    Hematol Oncol; 2012 Mar; 30(1):50-2. PubMed ID: 21574175
    [No Abstract]   [Full Text] [Related]  

  • 2. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.
    Musso M; Scalone R; Marcacci G; Lanza F; Di Renzo N; Cascavilla N; Di Bartolomeo P; Crescimanno A; Perrone T; Pinto A
    Bone Marrow Transplant; 2010 Jul; 45(7):1147-53. PubMed ID: 19898504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
    Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
    Au WY; Lie AK; Siu LL; Chan EC; Ooi GC; Leung AY; Liang R; Kwong YL
    Ann Hematol; 2003 Sep; 82(9):548-51. PubMed ID: 14504811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation.
    Lee KH; Lee JH; Lee JH; Kim WK; Chi HS; Lee JS
    Haematologica; 2001 Sep; 86(9):999-1001. PubMed ID: 11532635
    [No Abstract]   [Full Text] [Related]  

  • 6. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
    Buser AS; Stern M; Bucher C; Arber C; Heim D; Halter J; Meyer-Monard S; Stussi G; Lohri A; Ghielmini M; Tichelli A; Passweg JR; Gratwohl A
    Bone Marrow Transplant; 2007 Mar; 39(6):335-40. PubMed ID: 17342158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico.
    Llano OG; Perez JC; Rodriguez OC; Guerra CM; Aguirre HG; Garza JL; Rodriguez-Romo L; Almaguer DG
    Pediatr Hematol Oncol; 2008; 25(1):39-47. PubMed ID: 18231953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
    Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
    Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lomustine use in combination with etoposide, cytarabine and melphalan in a brief conditioning regimen for auto-HSCT in patients with lymphoma: the optimal dose.
    dos Santos KB; Costa LJ; Atalla A; Pereira J; Hallack-Neto AE
    Bone Marrow Transplant; 2014 Sep; 49(9):1239-40. PubMed ID: 24887380
    [No Abstract]   [Full Text] [Related]  

  • 10. Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.
    Martín A; Caballero MD; Pérez-Simón JA; López-Holgado N; Mateos MV; Cañizo MC; Miguel JF
    Bone Marrow Transplant; 2004 Oct; 34(8):675-82. PubMed ID: 15334049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic non-myeloablative stem cell transplantation for the patients with heavily pre-treated refractory lymphoma.
    Lee JH; Lee JH; Kang YK; Lee JS; Kim WK; Lee KH
    Haematologica; 2001 Oct; 86(10):1114-5. PubMed ID: 11602425
    [No Abstract]   [Full Text] [Related]  

  • 13. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
    Zohren F; Czibere A; Bruns I; Fenk R; Schroeder T; Gräf T; Haas R; Kobbe G
    Bone Marrow Transplant; 2009 Dec; 44(12):785-92. PubMed ID: 19430496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma.
    Scortechini I; Montanari M; Mancini G; Inglese E; Calandrelli M; Chiarucci M; Offidani M; Capelli D; Gini G; Poloni A; Mancini S; Raggetti G; Leoni P; Olivieri A
    Leuk Lymphoma; 2014 Jul; 55(7):1657-60. PubMed ID: 24024474
    [No Abstract]   [Full Text] [Related]  

  • 16. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
    Kashyap A; Snowden J
    J Rheumatol Suppl; 2001 Oct; 64():39-41. PubMed ID: 11642503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
    Anderlini P; Giralt S; Andersson B; Ueno NT; Khouri I; Acholonu S; Cohen A; Körbling MJ; Manning J; Romaguera J; Sarris A; Rodriguez ; Hagemeister F; Mclaughlin P; Cabanillas F; Champlin RE
    Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of a dose-adjusted fludarabine-melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma.
    Tendas A; Cupelli L; Dentamaro T; Scaramucci L; Palumbo R; Niscola P; Giovannini M; Piccioni D; Perrotti AP; de Fabritiis P
    Ann Hematol; 2009 Mar; 88(3):285-6. PubMed ID: 18690439
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.